Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.59 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249984 | 0.88 | PTPN7 (0.63) | MAPTTHRBKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL4253115 | 0.85 | PRSS12 (0.67) | MAPTKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL4918623 | 0.79 | PTPN7 (0.77) | MAPTLMNAKMT2AMEN1KDM4E | |
| SCHEMBL17916672 | 0.79 | PTPN7 (0.67) | MAPTLMNAKMT2AMEN1KDM4E | |
| SCHEMBL10596351 | 0.77 | RAB9A (0.82) | MAPTLMNAKMT2AMAPK1MEN1 | |
| SCHEMBL4252995 | 0.77 | LMNA (0.70) | MAPTLMNAKMT2AMAPK1MEN1 | |
| SCHEMBL25155011 | 0.77 | LMNA (1.00) | MAPTLMNAKMT2AMAPK1MEN1 | |
| SCHEMBL19771114 | 0.76 | POLB (0.74) | MAPTKMT2AMAPK1MEN1KDM4E | |
| SCHEMBL4246439 | 0.72 | SMN1; SMN2 (0.64) | MAPTLMNAKMT2AMAPK1MEN1 | |
| SCHEMBL10872798 | 0.72 | RAB9A (0.63) | MAPTLMNAKMT2AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | claimed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | CERS2, CHKB, SPHK2 | MAPT 1965/4885THRB 1489/4885LMNA 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.